摘要：In 2010, Clinical Research Center for Dementia of South Korea, a nation-wide clinical dementia research group, published the Clinical Practice Guideline for Dementia: Part 1, Diagnosis and Evaluation. This paper is the revised edition of the Clinical Practice Guideline for Dementia (Diagnosis and Evaluation). Since studies related to the diagnosis and evaluation of dementia are rapidly changing over the world, the latest evidence is required to revise the existing guideline. The Executive Committee for Guideline Development of the Korean Dementia Association updated recent changes related to the diagnosis and evaluation of dementia in this revised guideline. We used a hybrid development method, in which 8 different key questions not included in the existing guideline were used for the revision (
Table 1). In addition, relevant recommendations were made by evaluating the evidence with a
de novo method used for the revision. Notably, this revised guideline additionally describes subjective cognitive decline, which is regarded as a preclinical stage of Alzheimer’s disease, and amyloid positron emission tomography, a test method that can visually identify amyloid-β protein
in vivo. The revised edition of the Clinical Practice Guideline for Dementia (Diagnosis and Evaluation) was prepared using an evidence-based guideline production method along with a meta-analysis of the latest literature. Recommendations were made according to domestic situations based on evidence published so far. This guideline and recommendation will not only help neurologists and psychiatrists, but also help health care providers such as internists, family medicine specialists, and primary care physicians in their clinical decision-making.
